Modular PROTAC Design for Targeted Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing small molecule degraders and dimerizers are limited by a lack of understanding of the fundamental principles governing protein interactions, leading to inefficiencies in targeting and modulating specific proteins, particularly in cancer therapy where protein degradation is crucial.
Innovation Solution
The development of proteolysis targeting chimeras (PROTACs) as bivalent ligands that bind to a target protein and an E3 ligase via a linker, specifically utilizing Cereblon or Von Hippel-Lindau, to induce targeted protein degradation through the ubiquitin-proteasome pathway, and the creation of MDM2-based degraders to leverage the E3 ligase activity for therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If small molecule degraders are designed using conventional methods, then protein degradation can be achieved, but the process is inefficient and lacks fundamental understanding of protein interaction principles
Solution Approach 1:
The patent segments the degrader molecule into distinct functional modules: a target protein binding domain, a linker region, and an E3 ligase binding domain. This modular segmentation allows for systematic design and optimization of each component independently, improving the overall efficiency of protein degradation while making the design process more manageable and less complex.
Solution Approach 2:
The patent introduces a linker as an intermediary component that connects the target protein binding domain to the E3 ligase binding domain. This intermediary element mediates the spatial and functional relationship between the two binding domains, enabling effective protein degradation while providing a tunable parameter for optimizing degrader performance without increasing overall design complexity.
2Manufacturing precision
If PROTACs are used to induce targeted protein degradation, then specific proteins can be degraded, but the design requires deep understanding of protein-protein interactions which is currently lacking
Solution Approach 1:
The PROTAC molecule is divided into segmented functional domains: a target-specific binding moiety, a linker, and an E3 ligase binding moiety. This segmentation allows each domain to be optimized for its specific function independently, achieving high targeting specificity while reducing the need for comprehensive understanding of all protein-protein interaction principles.
Solution Approach 2:
The patent employs universal E3 ligase binding domains that can be paired with various target-specific binding moieties. This multi-functionality approach allows the same E3 ligase binding domain to work with different targets, reducing the knowledge burden on designers while maintaining high specificity for each target protein through its dedicated binding domain.
3Reliability
If MDM2-based degraders are developed to leverage E3 ligase activity, then therapeutic benefits can be achieved, but the development process is lengthy and costly
Solution Approach 1:
The patent performs preliminary actions by pre-optimizing the MDM2 binding domain and linker region before final degrader assembly. This preliminary optimization of key components accelerates the overall development process while ensuring therapeutic efficacy is achieved through pre-validated functional elements.
Solution Approach 2:
The patent systematically varies parameters such as linker length, composition, and MDM2 binding domain structure to optimize degrader performance. This parameter optimization approach efficiently identifies high-efficacy candidates while reducing development time by focusing computational and experimental resources on the most promising configurations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the specific degradation of proteins like AURKA, reducing their levels and activity, thereby providing a therapeutic benefit in treating cancers and other proliferative disorders by inducing apoptosis and preventing cellular proliferation.
Implementation Method 1
small molecule induced protein dimerization
Implementation Method 2
small molecule induced ubiquitination and degradation of disease targets
Implementation Method 3
The Ubiquitin-Proteasome Pathway (UPP) is a critical pathway regulating proteins and degrading misfolded or abnormal proteins
Data Source
AI summary
There are provided new heterobifunctional agents designed to mediate formation of protein-protein dimers and promote ubiquitination of a protein of interest component of the dimer. Also provided are methods of synthesizing the agents, pharmaceutical formulations including the agents, and methods of using the agents to treat, ameliorate or cure diseases characterized by protein over-expression or malfunction.